Regenxbio Plans to Resubmit Navsunli Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: stocktwits
- Resubmission Plan: Regenxbio intends to resubmit its Navsunli application in Q3, with this gene therapy aimed at replacing the faulty gene responsible for Hunter syndrome, which could significantly enhance the quality of life for patients if approved.
- Accelerated FDA Review: CEO Curran Simpson indicated that the FDA might expedite the review process post-resubmission, with a potential review timeline of as little as two months, thereby providing the company with quicker market access opportunities.
- Positive Market Reaction: Following the FDA's agreement to reconsider the Navsunli application, Regenxbio's shares surged 12% in pre-market trading, reflecting strong investor confidence in the therapy, despite a 44% decline in stock price this year.
- Impact of Hunter Syndrome: Hunter syndrome affects approximately 2,000 individuals globally, primarily boys, leading to progressive neurological decline; if Navsunli is approved, it would offer a revolutionary treatment option for this niche market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.020
Low
19.00
Averages
29.71
High
45.00
Current: 15.020
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
- Trial Launch: REGENXBIO announced the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial for diabetic retinopathy (DR), marking a significant milestone in its collaboration with AbbVie, which is expected to advance the clinical application of gene therapy.
- Funding Support: REGENXBIO will receive $100 million from AbbVie as a milestone payment, which not only strengthens the company's financial position but also provides funding for subsequent research, facilitating innovation in retinal disease treatment.
- Therapeutic Potential: Sura-vec, a one-time gene therapy, aims to improve long-term outcomes for DR patients by inhibiting vascular endothelial growth factor (VEGF), potentially transforming the current treatment paradigm that requires frequent interventions, thereby enhancing patient quality of life.
- Study Scale: The NAAVIGATE trial plans to enroll approximately 135 participants in the U.S. to primarily assess the safety and efficacy of sura-vec, and if successful, it will offer a new solution for DR treatment with significant market potential.
See More
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
- Trial Initiation: REGENXBIO announced the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial for diabetic retinopathy (DR), marking a significant milestone in its collaboration with AbbVie, which will yield a $100 million milestone payment, further advancing gene therapy clinical progress.
- Therapeutic Potential: Sura-vec demonstrated durable efficacy in the ALTITUDE trial with no intraocular inflammation observed in 15 patients, indicating its feasibility as a one-time treatment that could transform DR management and improve long-term visual outcomes for patients.
- Study Design: The NAAVIGATE trial aims to enroll approximately 135 participants in the U.S. to evaluate the safety and efficacy of sura-vec in non-proliferative DR patients without center-involved diabetic macular edema, with the primary endpoint being a greater than 2-step improvement on the diabetic retinopathy severity scale (DRSS) at one year.
- Future Outlook: REGENXBIO plans to present two-and-a-half-year data from the ALTITUDE trial at the 2026 ASRS Annual Meeting to further validate sura-vec's long-term efficacy, while also expecting to announce topline data from the ATMOSPHERE and ASCENT trials with AbbVie in Q4 2026, promoting its application in chronic retinal disease treatment.
See More
FDA's Regulatory Reversal Boosts Biotech Sector
- Regulatory Impact: Under the leadership of new acting commissioner Kyle Diamantas, the FDA has rapidly reversed decisions made by former commissioner Marty Makary, particularly those affecting rare disease therapies, benefiting biotech firms like UniQure (QURE) and Regenxbio (RGNX) with significant stock price increases.
- Gene Therapy Opportunities: UniQure's AMT-130 gene therapy has received a regulatory path forward from the FDA after a reassessment, which previously faced uncertainty under Makary, paving the way for potential market application and future growth for the company.
- Accelerated Approval Outlook: Regenxbio's RGX-121 gene therapy saw a substantial stock surge after the FDA agreed to its accelerated approval plan, indicating strong support from the new leadership for rare disease treatments, which may attract more investor interest.
- Positive Market Reaction: Since Diamantas took over, biotech stocks, as represented by the SPDR S&P Biotech ETF, have surged approximately 15%, while the S&P 500 remained flat, reflecting market optimism about the new policies and potentially encouraging more biotech firms to seek regulatory support.
See More
REGENXBIO Completes Dosing in RGX-202 Confirmatory Study
- Milestone Achieved: REGENXBIO has successfully completed dosing in the confirmatory study of RGX-202, positioning the company to initiate a Biologics License Application (BLA) in Q3 2026, with potential FDA approval in the second half of 2027, advancing treatment options for Duchenne muscular dystrophy.
- Data Supporting Application: The BLA submission will include safety data from 63 participants and efficacy data from 30 participants in the AFFINITY DUCHENNE® study, ensuring compliance with FDA accelerated approval criteria, highlighting RGX-202's advantages in clinical efficacy and safety profile.
- Market Readiness Accelerated: The company has initiated commercial supply production at its Manufacturing Innovation Center in Rockville, ensuring a rapid launch of RGX-202 post-FDA approval to meet the urgent market demand for Duchenne treatments, thereby enhancing its competitive position in the gene therapy sector.
- Innovative Therapeutic Mechanism: RGX-202 features a novel microdystrophin construct, combined with a proactive immune suppression regimen and high-purity manufacturing processes, aiming to provide maximum functional benefit and durability while maintaining a favorable safety profile, offering new hope for Duchenne patients.
See More
REGENXBIO Completes Confirmatory Study for RGX-202 Ahead of Schedule
- Study Completion Ahead of Schedule: REGENXBIO has successfully completed the confirmatory study for RGX-202 ahead of schedule, reflecting strong patient demand and investigator interest, positioning the company to submit a Biologics License Application (BLA) in Q3 2026, with potential FDA approval expected in H2 2027.
- Clinical Data Support: The BLA submission will include safety data from 63 participants and efficacy data from 30 participants, with RGX-202 achieving over 93% of patients reaching 10% microdystrophin expression at Week 12, demonstrating significant clinical effects.
- Significant Functional Improvement: Functional data from 9 patients at the 12-month assessment showed substantial improvements in multiple timed function tests and the North Star Ambulatory Assessment (NSAA), supporting RGX-202 as a potential new gene therapy option.
- Market Readiness: The company has initiated commercial supply production at its Manufacturing Innovation Center in Rockville, Maryland, ensuring a swift market launch post-FDA approval, further solidifying its leading position in the treatment of Duchenne muscular dystrophy.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
- Trial Launch: REGENXBIO announced the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial for diabetic retinopathy (DR), marking a significant milestone in its collaboration with AbbVie, which is expected to advance the clinical application of gene therapy.
- Funding Support: REGENXBIO will receive $100 million from AbbVie as a milestone payment, which not only strengthens the company's financial position but also provides funding for subsequent research, facilitating innovation in retinal disease treatment.
- Therapeutic Potential: Sura-vec, a one-time gene therapy, aims to improve long-term outcomes for DR patients by inhibiting vascular endothelial growth factor (VEGF), potentially transforming the current treatment paradigm that requires frequent interventions, thereby enhancing patient quality of life.
- Study Scale: The NAAVIGATE trial plans to enroll approximately 135 participants in the U.S. to primarily assess the safety and efficacy of sura-vec, and if successful, it will offer a new solution for DR treatment with significant market potential.
See More
REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy
- Trial Initiation: REGENXBIO announced the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial for diabetic retinopathy (DR), marking a significant milestone in its collaboration with AbbVie, which will yield a $100 million milestone payment, further advancing gene therapy clinical progress.
- Therapeutic Potential: Sura-vec demonstrated durable efficacy in the ALTITUDE trial with no intraocular inflammation observed in 15 patients, indicating its feasibility as a one-time treatment that could transform DR management and improve long-term visual outcomes for patients.
- Study Design: The NAAVIGATE trial aims to enroll approximately 135 participants in the U.S. to evaluate the safety and efficacy of sura-vec in non-proliferative DR patients without center-involved diabetic macular edema, with the primary endpoint being a greater than 2-step improvement on the diabetic retinopathy severity scale (DRSS) at one year.
- Future Outlook: REGENXBIO plans to present two-and-a-half-year data from the ALTITUDE trial at the 2026 ASRS Annual Meeting to further validate sura-vec's long-term efficacy, while also expecting to announce topline data from the ATMOSPHERE and ASCENT trials with AbbVie in Q4 2026, promoting its application in chronic retinal disease treatment.
See More
FDA's Regulatory Reversal Boosts Biotech Sector
- Regulatory Impact: Under the leadership of new acting commissioner Kyle Diamantas, the FDA has rapidly reversed decisions made by former commissioner Marty Makary, particularly those affecting rare disease therapies, benefiting biotech firms like UniQure (QURE) and Regenxbio (RGNX) with significant stock price increases.
- Gene Therapy Opportunities: UniQure's AMT-130 gene therapy has received a regulatory path forward from the FDA after a reassessment, which previously faced uncertainty under Makary, paving the way for potential market application and future growth for the company.
- Accelerated Approval Outlook: Regenxbio's RGX-121 gene therapy saw a substantial stock surge after the FDA agreed to its accelerated approval plan, indicating strong support from the new leadership for rare disease treatments, which may attract more investor interest.
- Positive Market Reaction: Since Diamantas took over, biotech stocks, as represented by the SPDR S&P Biotech ETF, have surged approximately 15%, while the S&P 500 remained flat, reflecting market optimism about the new policies and potentially encouraging more biotech firms to seek regulatory support.
See More
REGENXBIO Completes Dosing in RGX-202 Confirmatory Study
- Milestone Achieved: REGENXBIO has successfully completed dosing in the confirmatory study of RGX-202, positioning the company to initiate a Biologics License Application (BLA) in Q3 2026, with potential FDA approval in the second half of 2027, advancing treatment options for Duchenne muscular dystrophy.
- Data Supporting Application: The BLA submission will include safety data from 63 participants and efficacy data from 30 participants in the AFFINITY DUCHENNE® study, ensuring compliance with FDA accelerated approval criteria, highlighting RGX-202's advantages in clinical efficacy and safety profile.
- Market Readiness Accelerated: The company has initiated commercial supply production at its Manufacturing Innovation Center in Rockville, ensuring a rapid launch of RGX-202 post-FDA approval to meet the urgent market demand for Duchenne treatments, thereby enhancing its competitive position in the gene therapy sector.
- Innovative Therapeutic Mechanism: RGX-202 features a novel microdystrophin construct, combined with a proactive immune suppression regimen and high-purity manufacturing processes, aiming to provide maximum functional benefit and durability while maintaining a favorable safety profile, offering new hope for Duchenne patients.
See More
REGENXBIO Completes Confirmatory Study for RGX-202 Ahead of Schedule
- Study Completion Ahead of Schedule: REGENXBIO has successfully completed the confirmatory study for RGX-202 ahead of schedule, reflecting strong patient demand and investigator interest, positioning the company to submit a Biologics License Application (BLA) in Q3 2026, with potential FDA approval expected in H2 2027.
- Clinical Data Support: The BLA submission will include safety data from 63 participants and efficacy data from 30 participants, with RGX-202 achieving over 93% of patients reaching 10% microdystrophin expression at Week 12, demonstrating significant clinical effects.
- Significant Functional Improvement: Functional data from 9 patients at the 12-month assessment showed substantial improvements in multiple timed function tests and the North Star Ambulatory Assessment (NSAA), supporting RGX-202 as a potential new gene therapy option.
- Market Readiness: The company has initiated commercial supply production at its Manufacturing Innovation Center in Rockville, Maryland, ensuring a swift market launch post-FDA approval, further solidifying its leading position in the treatment of Duchenne muscular dystrophy.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
